Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bielack

Showing results (41-50 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapySabine Stegmaier, Stefan S Bielack, Ivo Leuschner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2006
Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System projectC A Stiller, S S Bielack, G Jundt, et al.
Anticancer Research|July 1, 1995
Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistanceS S Bielack, K Kallenbach, G Looft, et al.
Clinical Orthopaedics and Related Research|February 12, 1999
Local and systemic control after ablative and limb sparing surgery in patients with osteosarcomaM Sluga, R Windhager, S Lang, et al.
Cancer Management and Research|December 9, 2021
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma PatientsStefanie Hecker-Nolting, Thorsten Langer, Claudia Blattmann, et al.
Nuklearmedizin. Nuclear Medicine|January 1, 2000
High-activity samarium-153-EDTMP therapy in unresectable osteosarcomaC Franzius, S Bielack, J Sciuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study GroupS S Bielack, B Kempf-Bielack, U Heise, et al.
Journal of Cancer Research and Clinical Oncology|March 26, 2004
High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literatureB Leidinger, S Bielack, G Koehler, et al.
Bone Marrow Transplantation|July 4, 2001
High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcomaA Sauerbrey, S Bielack, B Kempf-Bielack, et al.
Nuklearmedizin. Nuclear Medicine|January 19, 2002
High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcomaC Franzius, S Bielack, S Flege, et al.
Pageof 19

Showing results (41-50 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapySabine Stegmaier, Stefan S Bielack, Ivo Leuschner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2006
Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System projectC A Stiller, S S Bielack, G Jundt, et al.
Anticancer Research|July 1, 1995
Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistanceS S Bielack, K Kallenbach, G Looft, et al.
Clinical Orthopaedics and Related Research|February 12, 1999
Local and systemic control after ablative and limb sparing surgery in patients with osteosarcomaM Sluga, R Windhager, S Lang, et al.
Cancer Management and Research|December 9, 2021
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma PatientsStefanie Hecker-Nolting, Thorsten Langer, Claudia Blattmann, et al.
Nuklearmedizin. Nuclear Medicine|January 1, 2000
High-activity samarium-153-EDTMP therapy in unresectable osteosarcomaC Franzius, S Bielack, J Sciuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study GroupS S Bielack, B Kempf-Bielack, U Heise, et al.
Journal of Cancer Research and Clinical Oncology|March 26, 2004
High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literatureB Leidinger, S Bielack, G Koehler, et al.
Bone Marrow Transplantation|July 4, 2001
High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcomaA Sauerbrey, S Bielack, B Kempf-Bielack, et al.
Nuklearmedizin. Nuclear Medicine|January 19, 2002
High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcomaC Franzius, S Bielack, S Flege, et al.
Pageof 19